BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Stock
Equities
603392
CNE100004090
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.26 CNY | +7.67% |
|
+2.31% | -9.14% |
| Sales 2024 * | 4.84B 669M | Sales 2025 * | 9.34B 1.29B | Capitalization | 86.57B 11.95B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.4B 193M | Net income 2025 * | 3.37B 466M | EV / Sales 2024 * | 16.8 x |
| Net cash position 2024 * | 5.27B 727M | Net cash position 2025 * | 5.25B 725M | EV / Sales 2025 * | 8.7 x |
| P/E ratio 2024 * |
63.4
x | P/E ratio 2025 * |
23.9
x | Employees | 3,843 |
| Yield 2024 * |
0.32% | Yield 2025 * |
0.28% | Free-Float | 18.23% |
More Fundamentals
* Assessed data
More news
| 1 day | +7.67% | ||
| 1 week | +2.31% | ||
| Current month | +0.92% | ||
| 1 month | -3.93% | ||
| 3 months | +13.13% | ||
| 6 months | +66.77% | ||
| Current year | -9.14% |
1 week
63.00
69.74
1 month
63.0081.50
Current year
47.6288.00
1 year
40.1488.00
3 years
40.14147.67
5 years
4.43147.67
10 years
4.43147.67
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Yong Zhao
DFI | Director of Finance/CFO | 53 | 07-12-31 |
Zi Xin Qiu
CHM | Chairman | 60 | 96-12-31 |
Hao Chen
ADM | Chief Administrative Officer | 42 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zi Xin Qiu
CHM | Chairman | 60 | 96-12-31 |
| 66 | - | ||
Qing Chao Xing
CHM | Chairman | 39 | 18-04-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.43% | 2 M€ | -16.59% | - | |
| 0.93% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 68.26 | +7.67% | 11,101,450 |
| 24-04-25 | 63.4 | -1.92% | 5,721,167 |
| 24-04-24 | 64.64 | -2.12% | 4,737,777 |
| 24-04-23 | 66.04 | -0.75% | 5,800,734 |
| 24-04-22 | 66.54 | -0.27% | 4,659,246 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Beijing Wantai Biopharmaceutical Co., Ltd. is a company mainly engaged in the research and development, production and sales of in-vitro diagnostics. The Company produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The Company is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
68.26
CNY
Average target price
70.4
CNY
Spread / Average Target
+3.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.14% | 11.95B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B | |
| +2.29% | 7.72B |
- Stock Market
- Equities
- 603392 Stock
